Highlight Therapeutics plans to open Series C funding round to continue with its investigation
Highlight Therapeutics planea abrir una ronda de financiación Serie C para continuar su investigación
Intel ID : 391496
|
||||
| Intel ID | 391496 | ||
| Value | ND | ||
| Native Currency | Euro (EUR) | ||
|
Financial Data - Highlight Therapeutics
(31 Dec 2020) |
Revenue: - People: 13 |
||
| Date |
 |
||
| Country |  |
||
| Geography | |
||
| Subsector (Old TTR Sectors) |
|
||
| Primary Subsector (TTRSC) |
30.01.99 Other Biotechnology & Pharmaceuticals (Primary) 30 Healthcare / 30.01 Biotechnology & Pharmaceuticals |
||
| Secondary Subsectors (TTRSC) |
15.06.01 Colleges & Universities 15 Consumer Products & Services / 15.06 Education & Training Services |
||
| Type |
|
||
| Intel Grade |
|
||
| Source |
|
||
| Tags | |
Target
| Name |
|
||
| Subsector (Old TTR Sectors) |
|
||
| Primary Sector (TTRSC) |
30.01.99 Other Biotechnology & Pharmaceuticals 30 Healthcare / 30.01 Biotechnology & Pharmaceuticals |
||
| Country |
|
||
| Website |
|
||
| Description |
|
Legend:
Verified: Confirmed as a party to an active or possible transaction.
Potential: Unconfirmed as a party to an active or possible transaction.
Retained: Confirmed as “Retained” with a general or specific mandate.
Prospect: Advisory “Prospect” in discussions with or pitching services to possible client.
Transactional data is continuously updated by the research team and therefore is subject to change.